3billion Showcases AI-Powered Variant Interpretation Innovation at ACMG 2026

• Leveraging its global diagnostic network spanning 75 countries to strengthen its presence in the North American market
• Live demonstrations of ‘GEBRA’, the company’s AI-powered variant interpretation platform, one year after its launch
• Reinforcing technical leadership among clinical geneticists and variant scientists worldwide

BALTIMORE, MD – March 10, 2026 – 3billion (CEO Changwon Keum), a leader in AI-powered rare disease diagnostics, today announced its participation in the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place March 10 -14 in Baltimore, Maryland.

The ACMG Annual Meeting is the world’s premier conference in medical genetics, bringing together clinical geneticists, researchers, and experts in genomic diagnostics and therapeutics to share the latest scientific advances and clinical standards. At this year’s event, 3billion will host a booth showcasing GEBRA,, its proprietary SaaS-based variant interpretation platform, as part of the company’s efforts to expand brand visibility among global clinical genetics experts.

3billion has demonstrated rapid growth by providing Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) –  based diagnostic services to medical institutions in 75 countries. Notably, the company’s revenue more than doubled last year, further strengthening its position in the global market. Building on its expanding global service network,GEBRA—first introduced at last year’s ACMG Annual Clinical Genetics Meeting—is now used by medical and research professionals in more than 20 countries worldwide. 

At this year’s meeting, 3billion is hosting live demonstrations of GEBRA’s enhanced variant interpretation capabilities, addressing the growing global need for rapid and accurate analysis of large-scale genomic data. GEBRA is a cutting-edge SaaS-based platform that uses AI to analyze hundreds of thousands of genetic variants in real time and prioritize potential diagnostic candidates. The platform is drawing strong interest for its ability to significantly improve diagnostic efficiency, particularly in clinical settings facing shortages of specialized personnel.

“ACMG Annual Clinical Genetics Meeting brings together leading experts in medical genetics from around the world and provides an important opportunity to showcase the clinical value of GEBRA and build trust with the global genetics community,”  said Changwon Keum, CEO of 3billion. “By leveraging our established global network, we aim to expand adoption of our AI-driven software and further strengthen our technical leadership in the global rare disease diagnostics market.”

Throughout the conference, 3billion’s on-site team will engage with leading North American hospitals and diagnostic laboratories to expand the company’s regional partnerships and business network.